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Daclizumab, a humanized monoclonal antibody against the α-chain of the IL-2 receptor (CD25) promotes tolerance in solid organ transplantation 1 , inflammatory uveitis 2 and multiple sclerosis [3] [4] [5] . This is unexpected, given that genetic deletion of CD25 leads to autoimmunity [6] [7] [8] [9] . It is now known that IL-2 not only promotes T cell expansion 10 but also plays a crucial part in the development of forkhead box P3 (FoxP3) + T regulatory cells (T reg cells) 11 and in the contraction of T cell responses 12 . Clearly, the latter mechanism predominates in genetic defects of CD25. However, daclizumab therapy also diminishes T reg numbers 13, 14 , indicating that other mechanisms must counteract the development of lymphoproliferation in daclizumab-treated individuals. We have reported that daclizumab expands CD56 bright natural killer (NK) cells, which contribute to the termination of immune responses by killing activated T cells 15 . We observed a strong correlation between CD56 bright NK cell expansion and inhibition of brain inflammation in daclizumab-treated patients 15 , suggesting that this expansion is linked to the therapeutic efficacy of daclizumab. However, we recently encountered an individual with multiple sclerosis in whom daclizumab inhibited brain inflammation without concomitantly expanding CD56 bright NK cells. This prompted us to search for an alternative mechanism of inhibition of T cell-mediated inflammation by daclizumab.
The IL-2 receptor (IL-2R) consists of three chains: two signaling chains, the β chain (CD122) and the common γ chain (γ c ; CD132), which together form an intermediate affinity IL-2R shared for signaling with IL-2 and IL-15, and the nonsignaling α chain CD25. Despite the fact that CD25 has very low affinity for IL-2 (K d ~10 nM), the quaternary IL-2R complex structure predicts that initial binding of CD25 to IL-2 stabilizes a secondary binding site for presentation to IL-2Rβ, which then recruits γ c , thus forming a high-affinity IL-2R (K d ~10 pM) 16 . The association of β and γ c chains induces signal transduction through the heterodimerization of their cytoplasmic domains, leading to activation of the Janus family tyrosine kinases Jak1 and Jak3 and subsequent phosphorylation of the transcription factor signal transducer and activator of transcription-5 (Stat5) 17 .
Both IL-2 and CD25 are linked to immune activation: CD25 is sparsely expressed on resting immune cells (with the exception of FoxP3 + T reg cells) but is readily upregulated on all T cells by both T cell receptor-and IL-2-mediated signaling 18 , as well as on macrophages and myeloid DCs upon activation with pathogen-associated molecular patterns (PAMPs) 19 . Whereas the main producers of IL-2 are activated T cells, IL-2 production has been described in mDCs 19, 20 , although its functional consequences remain undefined. Because CD25 expression on mDCs has been linked to their stimulatory capacity 21 , we decided to study the effect of daclizumab on mDC-mediated T cell activation.
RESULTS

Daclizumab inhibits T cell activation by mDCs
We incubated resting T cells with antigen-loaded myeloid mDCs in the presence of doses of daclizumab achievable in patients (10 µg ml −1 ) or a control CD25-specific antibody, MA-251, which does not block the IL-2-binding epitope. After 7-10 d, we evaluated T cell proliferation (Fig. 1) . We tested T cell responses to influenza hemagglutinin (Flu-HA; Whereas MA-251 had no inhibitory effect on T cell proliferation, daclizumab decreased the proportion of proliferating T cells by 78-88%, irrespective of the antigen used (Fig. 1c) . As Flu-HA-specific T cells produced higher amounts of cytokines than did HBP-specific T cells (data not shown), we used Flu-HA for all subsequent experiments. As a control, we reproduced our published observations 15 that the same concentration of daclizumab used in Figure 1c inhibits polyclonally activated T cells only minimally (Fig. 1d) .
Selective blockade of CD25 on DCs abrogates T cell expansion
Next we asked whether daclizumab exerts its inhibitory effect on T cells or mDCs. Thus, we preincubated either mDCs or T cells with daclizumab and washed away excess monoclonal antibody before assembling mDC-T cell cocultures. The selective blockade of CD25 on mDCs effectively inhibited T cell proliferation (Fig. 2a) , resulting in less accumulation of antigen-specific T cells (Fig. 2b) . To a lesser extent, blockade of CD25 on T cells also inhibited early T cell proliferation (days 5 to 9) (Fig. 2a,b) . However, in late stages of T cell proliferation, selective blockade of CD25 on T cells also inhibited the death of activated T cells, resulting in restored, or even heightened, accumulation of antigen-specific CD4 + T cells at day 14 of T-mDC cocultures (Fig. 2) .
CD25 − T cells proliferate if primed by CD25 + mDCs
In the previous experiment, CD25 blockade on T cells only partially inhibited antigen-driven proliferation. However, pretreatment of T cells with daclizumab does not block de novo synthesis of CD25 after T cell activation. Therefore, we used siRNA to block CD25 expression on T cells induced after activation. Inhibition of CD25 expression on T cells (by 56-95%) 24 h after stimulation (Supplementary Fig. 1a ) caused mild (2-30%) but reproducible inhibition of T cell proliferation (Supplementary Fig. 1b) . However, inhibition of CD25 expression on T cells also paradoxically increased the absolute number of cytokineproducing effector cells (Supplementary Fig. 1c,d) , confirming the role of high-affinity IL-2 signaling in activation-induced T cell death.
To unambiguously determine whether CD25 expression on T cells is dispensable for their activation, we performed experiments on T cells derived from an individual with a rare genetic deletion of CD25 (Fig. 3a) . Because the sample (obtained before this sick child underwent bone marrow transplantation) was too limited to establish DC cultures, we used mDCs derived from a major histocompatibility complex (MHC)-matched healthy donor. CD25 − T cells readily proliferated (Fig. 3b) , in response to three different antigens (keyhole limpet hemocyanin, glatiramer acetate (Copaxone) and were able to develop into cytokine-producing effector cells (Fig. 3c) as mDCs expressed CD25. Pretreatment of mDCs with daclizumab before coculture with CD25 − T cells caused more than 90% inhibition of T cell expansion, resulting in an almost complete lack of cytokineproducing effector cells (Fig. 3b,c ).
Fab domain mediates inhibitory effect of daclizumab
To exclude the possibility that daclizumab binds mDCs via Fc receptors and then inhibits CD25 on primed T cells via the antigenbinding domain (Fab), we used a version of daclizumab that lacks the Fc fragment (Dac-Fab) and found that it has an equivalent inhibitory effect to whole daclizumab ( Supplementary Fig. 2 ).
DCs lack IL-2Rb and therefore do not signal to IL-2 As previous experiments showed that the inhibitory effect of daclizumab on T cell proliferation resided in its ability to block CD25 on mDCs, we investigated whether IL-2 binding to mDCs induces signaling. Another group has reported that human DCs may express highaffinity IL-2R and that daclizumab inhibits mDC function [22] [23] [24] . Thus, we investigated the expression of IL-2R chains in myeloid DCs. We analyzed blood dendritic cell antigen-1 (BDCA-1) + DCs isolated from fresh human blood or apheresis samples (Fig. 4a) or monocyte-derived DCs (Fig. 4b) in their immature or mature stage and observed no expression of CD122 protein or mRNA ( Supplementary  Fig. 3a) . Consequently, we observed no IL-2-induced Stat5 phosphorylation ( Fig. 4c) in DCs from fresh human blood or in vitro-generated immature dendritic cells (iDCs) or mDCs. However, granulocytemacrophage colony-stimulating factor (GM-CSF) induced Stat5 phosphorylation in all DC subsets ( Fig. 4d ; peak phopshorylated Stat5 (pStat5) + DCs after 10-30 min of GM-CSF exposure: 86.9% in DCs present in fresh blood, 80.6% in iDCs and 51.2% in mDCs).
Even though we observed no Stat5 phosphorylation by DCs, we considered that IL-2 may provide a maturation signal to DCs through pathways other than Stat5 phosphorylation. However, we observed no effect on DC maturation of daclizumab, IL-2 or IL-2 in the presence of antibodies against the various chains of the IL-2R on DC maturation ( Supplementary  Fig. 3b) . Finally, the previously reported effects on DC maturation of daclizumab on DCs 22-24 could be due to the formation of immune complexes between daclizumab and CD25 expressed on the surface of the few contaminating T cells in the DC preparation, as immune complexes can inhibit the stimulatory capacity of DCs 25 . We observed that, when added to the maturation stimulus, immune complexes significantly inhibited DC maturation and CD25 expression (Supplementary Fig. 3b ).
mDCs use their CD25 to trans-present IL-2 to CD25 − T cells Because we observed no direct effect of IL-2 or daclizumab on DC maturation, we considered that, analogous to trans-presentation of IL-15 (ref. 26) , mDCs might use their CD25 to complement the T cell expression of β and γ c chains and facilitate assembly of the high-affinity IL-2R on T cells in trans.
To test this hypothesis, we first analyzed the time course of CD25 and IL-2 expression on polyclonally activated T cells. A small proportion of (memory) T cells produced IL-2 within the first hours after activation ( Supplementary Fig. 4) . However, these IL-2-producing T cells remained conspicuously CD25 negative for at least the first 10 h after activation. All T cells upregulated CD25 at later time points (≥24 h), but they also ceased to produce IL-2. This shutdown was IL-2 driven, as addition of IL-2-neutralizing antibody into T cell cultures restored IL-2 secretion (Supplementary Fig. 4 ). T cells activated in the presence of IL-2 resumed IL-2 production 48-72 h after stimulation, when they started to divide. The lack of CD25 expression on T cells within the first 10 h after activation supported our hypothesis that mDCs provide their CD25 to primed T cells for the formation of a high-affinity IL-2R. Thus, we tested the ability of mDCs to complement formation of high-affinity IL-2R on CD25 − T cells. First we evaluated whether CD25 + mDCs could restore Stat5 phosphorylation of daclizumab-pretreated T cells to exogenous IL-2 ( Supplementary Fig. 5 ). In this system, we observed only very low (on average 9.86%; nonsignificant) restoration of IL-2 signaling. In contrast to IL-15Rα's high affinity for IL-2, CD25's low affinity for IL-2 precludes it from effectively capturing IL-2 in situations when IL-2 can freely diffuse to the surroundings. Thus, we hypothesized that mDCs release IL-2 into the immune synapse, facilitating effective capture of IL-2 by mDC-derived CD25 and its trans-presentation to a primed T cell. Because of the low precursor frequency of antigen-specific T cells in blood, we had to switch to antigen-experienced T cells. We selected a long-term CD4 + T cell clone, P2-10 (ref. 27), specific for myelin basic protein (MBP 83-99 ) and several short-term (maximum 14 d from initial antigen-specific stimulation) CD4 + T cell lines specific for Flu-HA 306-318 , newly generated for each experiment. By including a short-term T cell line, we wanted to assure that no nonphysiological bias was introduced by long-term in vitro culture. We used these two antigen-specific systems interchangeably, loading syngeneic mDCs exogenously with cognate or noncognate peptide and confirmed our findings in both systems.
In the absence of exogenous IL-2, we observed strong Stat5 phosphorylation in T cells, which peaked 2 h after coculture with syngeneic mDCs loaded with cognate antigen (Fig. 5 and Supplementary Fig. 6a ). This Stat5 phosphorylation was significantly (P < 0.05) inhibited upon pretreatment of mDCs with daclizumab, whereas pretreatment of T cells with daclizumab had only a mild, nonsignificant inhibitory effect ( Fig. 5a and Supplementary Fig. 6a ). When we cocultured T cells with mDCs preloaded with noncognate antigen we observed no or little Stat5 phosphorylation, which was not amenable to inhibition by daclizumab. Notably, the level of mDC-induced Stat5 phosphorylation in T cells at this early stage of coculture correlated with the eventual expansion of antigen-specific effectors ( Fig. 5b and Supplementary Fig. 6b ). When we pooled data from multiple experiments, the Spearman's correlation coefficient between Stat5 phosphorylation and subsequent T cell expansion was R = 0.875 with P < 0.0001. To visualize formation of the immune synapse between T cells and mDCs, we used Amnis ImageStream technology, which allows visualization of mDC-T cell interactions with fluorescent microscopy and simultaneous quantification by flow cytometry (Fig. 5c,d) . In this experiment, we observed minimal Stat5 phosphorylation of T cells cultured in the absence of mDCs (0.17%; data not shown) or cultured with syngeneic mDCs pulsed with noncognate antigen (1.77%; Fig. 5c ). In contrast, coculture of T cells with cognate antigen-pulsed mDCs resulted in 75.1% pStat5 + CD4 + T cells (Fig. 5c) and even greater T cell Stat5 phosphorylation (86.7%) when T cells were fixed in contact with mDCs. Virtually all mDCs in contact with T cells expressed CD25 (Fig. 5d) . We also observed polarization of mDC-derived CD25 toward the immune synapse and the primed T cell. Pretreatment of mDCs with daclizumab resulted in decreased numbers of pStat5 + T cells (34.3%; Fig. 5c ), which was slightly higher than the proportion of T cells that expressed CD25 in this experiment (22.6-27.7%).
mDCs and T cells secrete IL-2 in an antigen-specific manner As our previous experiment implied that the observed Stat5 phosphorylation was IL-2 driven, we wanted to visualize IL-2 secretion in mDC-T cell cocultures. Using an IL-2 secretion assay, in which the IL-2 secreted during cocultures is captured by an IL-2 catch reagent and later visualized on the surface of the cell that released it, we observed that very few mDCs and T cells secreted IL-2 when they were cultured alone (Fig. 6a) . When the T cells were cultured in the presence of syngeneic mDCs loaded with cognate antigen, strong IL-2 secretion was induced both in mDCs and T cells (Fig. 6a) within the first 2 h of coculture. In contrast, coculture of T cells with mDCs loaded with noncognate antigen leads to a decrease in IL-2 secretion by mDCs even below baseline levels (Fig. 6a) .
Visualization of IL-2 secretion by Amnis ImageStream (Fig. 6b) confirmed that either T cells or mDCs can be the source of secreted IL-2 in the antigen-specific system. Furthermore, IL-2 was secreted preferentially into the immune synapse, especially by mDCs, as visualized in enlarged images of the immune synapse (Supplementary Fig. 7 ).
DISCUSSION
Although DCs produce IL-2 after microbial stimulation 20, 28 , and the expression of CD25 is an activation marker on mDCs 21, 22, 29 , the relevance of these observations for T cell activation has been unclear 30 .
In agreement with mouse data 30,31 , we observed that human myeloid DCs lack expression of IL-2R β chain (CD122), which is essential for IL-2 signaling 18 . Consequently, IL-2 failed to phosphorylate Stat5 in DCs and failed to affect the DC maturation phenotype. Therefore, we concluded that the CD25 on myeloid mDCs must have a different role than facilitating IL-2 signaling in DCs. We hypothesized that mDCs use their CD25 for targeted IL-2 delivery to primed T cells. This type of presentation in trans was already described for IL-15 (ref. 26 ), a cytokine closely related to IL-2, which uses identical intermediate affinity receptor chains. However, in contrast to the stable interaction of IL-15Rα with IL-15 (ref. 26 ), CD25 has low affinity for IL-2. Yet a biophysical model predicts that IL-2 binding of CD25 initiates the formation of a high-affinity IL-2R 16 . How can CD25 fulfill this key role under situations of low IL-2 concentration, such as at the initiation of the immune response, when pathogen-associated molecular patternactivated mDCs may be the only source of IL-2? We hypothesized that directional secretion of IL-2 into the immune synapse would limit diffusion of IL-2 and facilitate its binding to CD25. Indeed, we observed strong Stat5 phosphorylation of T cells after coculture with syngeneic mDCs loaded with cognate antigen. Furthermore, the Stat5 phosphorylation in antigen-specific T cells was substantially inhibited by selective blockade of CD25 on the surface of mDCs. Stat5 phosphorylation was only slightly increased when T cells were cocultured with syngeneic CD25 + mDCs loaded with noncognate antigen, probably owing to the fact that we observed no IL-2 secretion in such a setting. With antigen-experienced T cells, we observed that both mDCs and T cells secrete IL-2, although strictly in an antigen-specific manner. However, when we polyclonally activated resting T cells purified from human blood, we observed that only a small proportion of them were capable of secreting IL-2 within first 10 h after activation, and virtually none of those expressed CD25. We believe that this is more reminiscent of the priming of naive T cells; these T cells do not express CD25 and do not secrete IL-2 within the first few hours of antigen stimulation, making them entirely dependent on mDCs to facilitate their early IL-2 signaling. In contrast, memory/effector T cells may contribute their own CD25, IL-2 or both when primed by mDCs, effectively lowering their stimulation requirements. Yet, the high-affinity IL-2 signal received during T cell priming seems to be a major determinant of subsequent T cell expansion, even for antigen-experienced T cells. Our current model (Supplementary Fig. 8 ) predicts why immunodeficiency of adaptive T cell responses dominates the phenotype of humans with CD25 deficiency and coexists with paradoxical lymphoproliferation [7] [8] [9] 32 . This model predicts that although CD25 deficiency would negatively affect development of antigen-specific effectors, it would not inhibit homeostatic T cell proliferation. Indeed, we observed that IL-7 can drive T cell proliferation in the presence of daclizumab, although it does not fully restore development of antigenspecific effectors (data not shown). Our model also explains the paradoxical observation that although complete (>99%) saturation of CD25 in blood lymphocytes is achieved with low doses of daclizumab (blood concentrations of 1 µg ml −1 ), therapeutic efficacy increases with higher doses 4, 33 . We predict that saturation of CD25 in lymph nodes and tissues is required for the full therapeutic effect of daclizumab in transplantation and autoimmunity.
In conclusion, our data have suggested a mechanism that highlights how the expression of cytokine signaling chains on various cells of the immune system can divergently regulate T cell functions through a single cytokine. This knowledge not only enhances understanding of the complexities of immunoregulation in vivo but also represents a basis for the development of more effective IL-2 and CD25-targeting therapies.
METhODS
Methods and any associated references are available in the online version of the paper at http://www.nature.com/naturemedicine/.
Note: Supplementary information is available on the Nature Medicine website.
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Study subjects. Studies were performed in accordance with the guidelines of the NINDS Institutional Review Board, and all subjects signed informed consent. Unless stated otherwise, study subjects were healthy donors.
Isolation of PBMCs and generation of DCs. PBMCs were isolated from apheresis by lymphocyte separation medium (Lonza). CD14 + monocytes were isolated by positive selection (IMag, BD; purity routinely >92%) from PBMCs and plated in Iscove's Modified Dulbecco's Medium containing 100 ng ml −1 recombinant human GM-CSF, 100 ng ml −1 recombinant human IL-4 (PeproTech) and 5% human serum (for 5-6 d). Medium was replenished every 3 d. iDCs were washed and incubated with either Flu-HA (0.5 µg ml −1 ; Sanofi Pasteur), HBP (10 µg ml −1 ; Clontech), keyhole limpet hemocyanin (10 µg ml −1 ; Sigma-Aldrich) or glatiramer acetate (Copaxone, 10 µg ml −1 ; Teva Marion Partner). Maturation cocktail (50 ng ml −1 TNF-α, 10 ng ml −1 IL-1β, 150 ng ml −1 IL-6 (all PeproTech) and 1 µg ml −1 prostaglandin E 2 ) was added 24 h after antigen, and cells were incubated for additional 2-3 d. DC phenotype was characterized by staining for CD11c, CD25, CD80, CD83, CD122, CD132 and MHC-II (BD Biosciences).
T cell proliferation assays. T cells were purified from PBMCs by negative selection (Pan T cell Isolation Kit II; Miltenyi Biotech; purity routinely >95%) and labeled with CFSE as previously described 15 . CFSE-stained T cells were cultured with autologous antigen-loaded mDCs (5-10 T cells: 1 mDC) in the presence of 10-20 µg ml −1 daclizumab (Roche) or equivalent concentration of daclizumabFab or MA-251 control antibody (BD Biosciences). These doses of daclizumab are achievable in vivo in current multiple sclerosis dosing regimens 15 . Absolute numbers of proliferating cells were determined by normalizing to allophycocyanin-labeled beads (BD Biosciences). Alternatively, mDCs were pretreated with daclizumab, daclizumab-Fab or MA-251 (30-60 min at 37 °C) before coculture. After 5-14 d, T cell cultures were analyzed for CFSE dilution and intracellular cytokine detection as previously described 15 . Data were analyzed with BD FACSDiva 6.1 (BD Biosciences).
Flow cytometry-based signaling assays. Signaling assays were performed using BD Phosflow protocols as previously described 13 . Briefly, cells were cultured in the presence or absence of exogenous IL-2 (50 IU ml −1 ) or 200 ng ml −1 of GM-CSF for the indicated time periods (Fig. 4c,d, Fig. 5 and Supplementary  Fig. 6 ). Afterward, cells were fixed, permeabilized and stained for pStat5 (pTyr694; clone 47), CD3 (SK7), CD4 (RPA-T4), CD8 (RPA-T8), CD11c (B-ly6) (all BD Biosciences), HLA-DR (LN3; eBiosciences) and CD25 (B1.49.9; Beckman Coulter). In the indicated conditions ( Fig. 5 and Supplementary  Fig. 6 ), mDCs and T cells were pretreated with 20 µg ml −1 daclizumab (0.5-1 h, 37 °C), and cocultured. For ex vivo signaling assays, fresh uncoagulated whole blood was stimulated with exogenous cytokines, lysed, fixed by Phosflow Lyse/Fix Buffer (BD) and processed according to the manufacturer's protocol.
Flow cytometry-based IL-2 secretion assay. IL-2 secretion of cocultured mDCs and T cells was analyzed with the IL-2 Secretion Assay Detection Kit (APC) from Miltenyi Biotech. mDCs were loaded with 1 µM MBP 83-99 or Flu-HA 306-318 and incubated for 1 h at 37 °C. After washing, different conditions of antigen-loaded mDCs and T cells were assembled. One and two hours after coculture, cells were labeled with IL-2 catch reagent and incubated for 45 min. Subsequently, cells were labeled with IL-2 detection antibody and appropriate surface markers.
